Atara生物醫藥 ATRA 深 滬
等待開盤 07-18 09:30:00 美东时间
9.71
+0.430
+4.63%
華盛通- 最 高9.80
- 今 開9.30
- 成交量 7.92万股
- 最 低 8.53
- 昨 收 9.28
- 總市值 6598.53万
- 52周最高 18.705
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 5.005
- 委 比 -83.47%
- 總股本 679.56万
- 歷史最高 1639.00
- 量 比 1.87
- 振 幅 13.69%
- 歷史最低 4.965
- 每 手 1
- 風險率 6.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pierre Fabre Pharma Announces Transfer Of IND Application For Tabelecleucel From Its Partner, Atara Biotherapeutics
Pierre Fabre Laboratories is now responsible for all global clinical trial activities for the tabelecleucel clinical programEnrollment is ongoing for pivotal, Phase 3 ALLELE Study (NCT03394365) investigating
07-15 20:19
Zura Bio appoints Eric Hyllengren as CFO
Zura Bio (NASDAQ:ZURA) has announced the appointment of Eric Hyllengren as CFO, effective July 7, 2025. He will succeed Verender Badial, who will step down from the role and remain with the company as...
07-01 19:44
Atara Biotherapeutics Holds Annual Stockholders Meeting
Atara Biotherapeutics ( ($ATRA) ) has provided an update. On June 10, 2025, Ata...
06-12 04:57
Atara Biotherapeutics Announces $16M Stock Offering
Atara Biotherapeutics ( ($ATRA) ) has shared an announcement. On May 14, 2024, ...
05-17 05:48
Atara Biotherapeutics Q1 EPS $3.50 Beats $(1.98) Estimate, Sales $98.15M Beat $5.67M Estimate
Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly earnings of $3.50 per share which beat the analyst consensus estimate of $(1.98) by 276.77 percent. This is a 160.87 percent increase over losses of $(5.75) per
05-15 21:17
Atara Biotherapeutics Appoints New Board Members Amid Restructuring
Atara Biotherapeutics ( ($ATRA) ) has shared an update. On May 14, 2025, Atara ...
05-15 20:57
Atara Biotherapeutics prices $16M public offering
Atara Biotherapeutics (NASDAQ:ATRA) announced the pricing of an offering of 834,237 shares of common stock at $6.61/share and pre-funded warrants to purchase 1.59M shares of common stock at $6.6099/pr...
05-15 20:42
Atara Biotherapeutics Prices Offering Of 834,237 Shares At $6.61/Shr And Pre-Funded Warrants At $6.6099 Per Pre-Funded Warrant Share In Underwritten Registered Direct Offering
Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
05-15 20:36
Atara Biotherapeutics to reduce workforce by 30%
Atara Biotherapeutics (NASDAQ:ATRA) announced on Monday a reduction in its workforce that will impact approximately 30% of its current employees, retaining approximately 23 employees essential to exec...
05-13 04:22
FDA Lifts Hold on Atara’s EBVALLO Program
An announcement from Atara Biotherapeutics ( ($ATRA) ) is now available. On May...
05-07 04:50
